-
PSG blow as Hakimi ruled out of Champions League semi-final return
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Trump says US has 'a shot' at crewed Moon landing before presidency ends
-
Hungary's Magyar pushes to unblock EU billions in Brussels
-
London police probe 'terror' incident after two Jewish men stabbed
-
Rob Reiner autopsy report not ready, court hears
-
Rickelton ton in vain as Hyderabad chase down 244 to beat Mumbai
-
US Fed divided at Powell's likely last meeting at helm
-
Draper out of French Open in fresh injury blow
-
King Charles touts 'solidarity' with US at 9/11 memorial
-
Ticket price hikes not affecting summer air travel demand: IATA
-
Liverpool 'expect Salah to be available' before Anfield exit
-
World snooker champion Zhao Xintong succumbs to 'Crucible curse'
-
Australia FM says China agrees to collaborate on jet fuel exports
-
Pentagon chief spars with Democratic lawmakers on Iran war
-
Hungary's Magyar pushes to unblock EU billion in Brussels
-
Departing US still owes money, says WHO chief
-
Joshua warm-up defeat would 'kill' Fury fight, warns promoter Warren
-
Sinner stops Jodar to book spot in Madrid Open semis
-
Pogacar wins opening full stage to take Tour de Romandie lead
-
'River on fire': Toxic fumes as Ukrainian drones pound Russian oil town
-
Pereira aiming to bring European glory back to Forest
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
-
Two Jewish men stabbed in 'terrorist' attack in London
-
End of an era: last hereditary peers exit UK parliament
-
Canada holds key rate steady, says will act if war inflation persists
-
Emery aims to write 'new chapter' in Europe with Villa
-
US Supreme Court curbs race-based voting maps in landmark ruling
-
Guerrillas claim deadly Colombia attack, say it was an 'error'
-
Trump warns Iran better 'get smart soon' and accept nuclear deal
-
UN experts urge Saudi labour practices switch before World Cup
-
Oil spikes while stocks slide ahead of US Fed rate decision
-
US Fed chief's plans in focus as central bank set to hold rates steady
-
Tuareg rebels vow Mali junta 'will fall', north will be captured
-
German inflation jumps in April as energy costs surge
-
Was PSG against Bayern the Champions League's greatest ever game?
-
UBS first-quarter profits jump 80% on investment banking
-
France's 'roadmap' to exit fossil fuels by 2050
-
Chelsea captain Millie Bright retires
-
Bangladesh measles outbreak kills over 220 children since March
-
Finnish lift maker Kone acquires German rival TKE, creating giant
-
Hungary's Magyar visits Brussels seeking to unblock EU billions
-
Diving robot explores mystery of France's deepest shipwreck
-
Thai ex-PM Thaksin to be released from prison next month
-
Welsh rugby great North to hang up his boots
-
Much-needed rains revive Iraq's fabled Mesopotamian Marshes
-
French teen in straw licking case allowed to leave Singapore
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 261008. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52943, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
[email protected]
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
R.Chavez--AT